Joleen Hubbard is an Oncology physician affiliated with Allina Health. OpenAlex indexes 288 publications with 8,557 citations (h-index 34); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 16 Jan 2024.
Clinical trials
- Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Sponsor: Treos Bio Limited
- Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202514 payments$13,685openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36.9%Serotonin-3 Receptor Antagonist29.1%Ondansetron Hcl100%Part D≥37 patientsOpioid Agonist7.8%Loperamide100%Part D<11 patientsNervous system
32.4%Phenothiazine32.4%Prochlorperazine Maleate100%Part D≥39 patientsSensory organs
23.5%Corticosteroid23.5%Dexamethasone100%Part D≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Journal for ImmunoTherapy of Cancer
2023 - Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.
Journal of Clinical Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Frank Rhame, MD
Allina Health
Brian Swiglo, MD
Allina Health
Craig Strauss, MD, MPH
Allina Health
Jesse Corry, MD
Allina Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”